The study reframes neuropathy as a key determinant of tissue recovery rather than an irreversible endpoint.

BREA, Calif., Jan. 21, 2026 /PRNewswire/ — Rapid Nexus Nanotech Wound Solutions, Inc., a California-based medical technology company, today announced the publication of a peer-reviewed study documenting outcomes that challenge long-held assumptions about neuropathy-driven tissue damage and limb loss.

The study reports that tissue previously considered beyond recovery — and slated for surgical amputation — was able to stabilize and heal when peripheral neuropathy was directly addressed through a targeted nerve signaling intervention. These findings suggest that neuropathy plays a central, previously underappreciated role in determining whether damaged tissue can recover, rather than serving as a fixed, irreversible condition.

Peripheral neuropathy affects millions of patients worldwide and is commonly associated with diabetes, vascular disease, and trauma. Over time, progressive nerve dysfunction disrupts blood flow regulation, immune

 response, and cellular repair mechanisms — contributing to chronic tissue breakdown, recurrent wounds, loss of mobility, and, ultimately, amputation. Standard wound-care approaches largely focus on managing surface-level damage, infection, or moisture balance, without addressing the underlying nerve dysfunction that prevents tissue from repairing itself.

In the peer-reviewed study, researchers observed that when nerve signaling at the tissue level was restored, the biological conditions necessary for healing re-emerged — even in advanced cases where tissue had been deemed non-salvageable. Rather than treating tissue loss as inevitable, the findings point to neuropathy as a modifiable driver of tissue failure and recovery.

“Neuropathy has long been treated as an endpoint — something clinicians manage around rather than address directly,” said Dr. Margaret Kalmeta, inventor and founder of Rapid Nexus Nanotech Wound Solutions, Inc. “This study suggests that when nerve signaling is restored, the body may regain the ability to stabilize and heal tissue that would otherwise be lost. That represents a fundamental shift in how we think about recovery in advanced disease.”

The study adds to a growing body of evidence suggesting that nerve function plays a decisive role in tissue viability, immune response, and vascular regulation. By reframing neuropathy as a determinant of recovery rather than an irreversible decline, the findings may have implications beyond wound care, including mobility preservation and long-term quality of life for patients with progressive nerve damage.

Rapid Nexus’s technology was developed to target the underlying biological mechanisms that prevent healing, rather than simply managing visible damage. The company’s approach is currently being evaluated across multiple clinical settings, with the goal of expanding access to treatments that intervene earlier in the disease process and reduce the need for limb amputation.

The peer-reviewed publication represents an important milestone as Rapid Nexus continues to engage with clinicians, health systems, and researchers to explore broader applications of neuropathy-focused interventions.

About Rapid Nexus Nanotech Wound Solutions, Inc.

Rapid Nexus Nanotech Wound Solutions, Inc. is a California-based medical device company developing technologies designed to address the underlying biological drivers of chronic tissue damage and neuropathy-related complications. The company’s work focuses on restoring physiological conditions that enable tissue stability and recovery in patients with diabetes, trauma, and vascular disease.

Media Contact

press@rapidnexus.com

Top Media Coverage
This announcement has been featured in:
• Yahoo Finance
• Benzinga
• PR Newswire